Treatment of early (I, IIA/B) stages of germinomas of the testis
- Authors: Tryakin A.A.1, Bulanov A.A.1, Tyulyandin S.A.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Issue: Vol 2, No 4 (2006)
- Pages: 53-58
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. TESTICULAR CANCER
- Published: 30.12.2006
- URL: https://oncourology.abvpress.ru/oncur/article/view/1154
- DOI: https://doi.org/10.17650/1726-9776-2006-2-4-53-58
- ID: 1154
Cite item
Full Text
Abstract
Germinomas of the testis are most commonly presented in early (I-II) stages. In Stage T, choice of adjuvant therapy is based on the type of a tumor, the presence of risk factors, and a patient’s wishes. Seminoma requires monitoring, radiotherapy (20 Gy paraaortically) or chemotherapy (a course pf carboplatin therapy), non-seminomic testicular tumors call for monitoring, nerve-preserving retroperitoneal lymphadenectomy (NPRLAE) or chemotherapy (2 courses of ВЕР). All treatment modalities ensure recovery in above 95% of patients. In Stage II, the similar results can be achieved by radiotherapy or chemotherapy (3 courses of ВЕР) in patients with seminoma, by NPRLAE or chemotherapy (3 courses of ВЕР) in patients with non-seminomic tumors of the testis. The equal efficiency of all approaches generates a need for discussing all possible treatment modalities with the patient, by taking into account toxicity and convenience.
About the authors
A. A. Tryakin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Author for correspondence.
Department of Clinical Pharmacology and Chemotherapy Russian Federation
A. A. Bulanov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesDepartment of Clinical Pharmacology and Chemotherapy Russian Federation
S. A. Tyulyandin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesDepartment of Clinical Pharmacology and Chemotherapy Russian Federation
References
Supplementary files

